News
22h
Zacks.com on MSNMRUS Stock Soars 30% in 3 Months After Phase II Cancer Study SuccessMerus jumps 30% in three months after its cancer combo therapy showed significant efficacy in a phase II head and neck squamous cell carcinoma study.
Two brothers from India were each sentenced to 30 months in prison for a scheme to sell counterfeit and adulterated drugs in ...
MSFT, BABA, and MRK lead today's top analyst picks, with AI, e-commerce, and cancer drug strategies in sharp focus.
7h
MONTCO Today on MSNWSJ: Merck Makes $10 Billion Move as Keytruda Patent Expiration NearsMerck is making big pharma waves again with a $10 billion deal to acquire Verona Pharma, reports Colin Kellaher for the Wall ...
The main patent for Ohtuvayre, the COPD drug at the heart of Verona’s $10 billion sale, expired in 2020. For Merck to make ...
21hon MSN
The participants in the trial – similar to two-thirds of breast cancer patients overall - had tumors that use the hormones estrogen and progesterone to grow. The goal of so-called endocrine therapy is ...
Pharmaceutical titan Merck & Co. Inc. has announced a landmark $10 billion acquisition of Verona Pharma plc, underscoring its ...
Freshfields lands major US mandate advising Merck on $10bn Verona Pharma acquisition opposite Latham
Freshfields is advising Merck on its $10bn acquisition of respiratory-focused pharmaceutical company Verona Pharma, in a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results